JPWO2022149578A1 - - Google Patents

Info

Publication number
JPWO2022149578A1
JPWO2022149578A1 JP2022539057A JP2022539057A JPWO2022149578A1 JP WO2022149578 A1 JPWO2022149578 A1 JP WO2022149578A1 JP 2022539057 A JP2022539057 A JP 2022539057A JP 2022539057 A JP2022539057 A JP 2022539057A JP WO2022149578 A1 JPWO2022149578 A1 JP WO2022149578A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022539057A
Other languages
Japanese (ja)
Other versions
JPWO2022149578A5 (https=
JP7154465B1 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022149578A1 publication Critical patent/JPWO2022149578A1/ja
Priority to JP2022160447A priority Critical patent/JP7846599B2/ja
Application granted granted Critical
Publication of JP7154465B1 publication Critical patent/JP7154465B1/ja
Publication of JPWO2022149578A5 publication Critical patent/JPWO2022149578A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G4/00—Radioactive sources
    • G21G4/04—Radioactive sources other than neutron sources
    • G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
    • G21G4/08—Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022539057A 2021-01-08 2022-01-05 Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法 Active JP7154465B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022160447A JP7846599B2 (ja) 2021-01-08 2022-10-04 Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021002437 2021-01-08
JP2021002437 2021-01-08
PCT/JP2022/000116 WO2022149578A1 (ja) 2021-01-08 2022-01-05 Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022160447A Division JP7846599B2 (ja) 2021-01-08 2022-10-04 Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法

Publications (3)

Publication Number Publication Date
JPWO2022149578A1 true JPWO2022149578A1 (https=) 2022-07-14
JP7154465B1 JP7154465B1 (ja) 2022-10-17
JPWO2022149578A5 JPWO2022149578A5 (https=) 2022-12-14

Family

ID=82357768

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022539057A Active JP7154465B1 (ja) 2021-01-08 2022-01-05 Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法
JP2022160447A Active JP7846599B2 (ja) 2021-01-08 2022-10-04 Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022160447A Active JP7846599B2 (ja) 2021-01-08 2022-10-04 Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法

Country Status (10)

Country Link
US (2) US11752223B2 (https=)
EP (1) EP4276855A4 (https=)
JP (2) JP7154465B1 (https=)
KR (2) KR102500942B1 (https=)
CN (1) CN116711028A (https=)
AU (1) AU2022206140A1 (https=)
CA (1) CA3207700A1 (https=)
TW (1) TW202235093A (https=)
WO (1) WO2022149578A1 (https=)
ZA (1) ZA202306906B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233247A (zh) * 2020-10-16 2022-09-01 日商日本醫事物理股份有限公司 抗ｈｅｒ２抗體之放射性複合體及放射性醫藥
WO2026063503A1 (ja) * 2024-09-20 2026-03-26 日本メジフィジックス株式会社 Ａｃ－２２５溶液の製造方法および該溶液を用いたＡｃ－２２５標識錯体の製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07203974A (ja) 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
JPH115749A (ja) 1997-06-13 1999-01-12 Tosoh Corp 癌治療医薬品組成物
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
US7282567B2 (en) * 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
US7087206B2 (en) * 2002-04-12 2006-08-08 Pg Research Foundation Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine
DE10347459B3 (de) 2003-10-13 2005-05-25 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
WO2005084179A2 (en) * 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
DE102006042191B4 (de) * 2005-09-09 2010-08-05 Actinium Pharmaceuticals, Inc. Verfahren zur Reinigung von Radium aus verschiedenen Quellen
DE102006008023B4 (de) * 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets
CA2662932C (en) 2006-09-08 2017-06-06 Actinium Pharmaceuticals, Inc. Method for the purification of radium from different sources
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157102A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
DE102014115154A1 (de) * 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
US10227383B2 (en) 2015-05-20 2019-03-12 Kagoshima University Specific modification of antibody with IgG-binding peptide
SG10202012408UA (en) 2016-06-13 2021-01-28 Univ Kagoshima SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE
CN118430866A (zh) * 2017-06-29 2024-08-02 南非核能Soc有限公司 放射性同位素的制备
KR102533289B1 (ko) 2019-06-19 2023-05-17 니혼 메디피직스 가부시키가이샤 226Ra 타깃의 제조 방법, 225Ac의 제조 방법 및 226Ra 타깃 제조용 전착액
KR102490805B1 (ko) * 2019-07-02 2023-01-20 니혼 메디피직스 가부시키가이샤 226Ra 함유 용액의 정제 방법, 226Ra 타깃의 제조 방법, 및 225Ac의 제조 방법
KR20220047974A (ko) 2019-08-21 2022-04-19 니혼 메디피직스 가부시키가이샤 방사성 금속 착체의 제조 방법
PH12022550919A1 (en) 2019-10-18 2023-07-10 Nihon Mediphysics Co Ltd Method for producing radioactive metal-labeled antibody

Also Published As

Publication number Publication date
CN116711028A (zh) 2023-09-05
JP2022188190A (ja) 2022-12-20
KR20220101191A (ko) 2022-07-19
EP4276855A4 (en) 2025-08-06
US20230364275A1 (en) 2023-11-16
ZA202306906B (en) 2024-10-30
KR102500942B1 (ko) 2023-02-17
TW202235093A (zh) 2022-09-16
AU2022206140A1 (en) 2023-07-27
JP7846599B2 (ja) 2026-04-15
US11752223B2 (en) 2023-09-12
WO2022149578A1 (ja) 2022-07-14
KR20230120627A (ko) 2023-08-17
CA3207700A1 (en) 2022-07-14
US20220370651A1 (en) 2022-11-24
JP7154465B1 (ja) 2022-10-17
EP4276855A1 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
JPWO2022149578A1 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220623

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221004

R150 Certificate of patent or registration of utility model

Ref document number: 7154465

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250